TW200507858A - Formulations of glucocorticoids to treat pathologic ocular angiogenesis - Google Patents

Formulations of glucocorticoids to treat pathologic ocular angiogenesis

Info

Publication number
TW200507858A
TW200507858A TW093104085A TW93104085A TW200507858A TW 200507858 A TW200507858 A TW 200507858A TW 093104085 A TW093104085 A TW 093104085A TW 93104085 A TW93104085 A TW 93104085A TW 200507858 A TW200507858 A TW 200507858A
Authority
TW
Taiwan
Prior art keywords
formulations
glucocorticoids
ocular angiogenesis
pathologic ocular
treat pathologic
Prior art date
Application number
TW093104085A
Other languages
English (en)
Chinese (zh)
Inventor
David P Bingaman
Abbot F Clark
Rajni Jani
Stella M Robertson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of TW200507858A publication Critical patent/TW200507858A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093104085A 2003-02-20 2004-02-19 Formulations of glucocorticoids to treat pathologic ocular angiogenesis TW200507858A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44894403P 2003-02-20 2003-02-20

Publications (1)

Publication Number Publication Date
TW200507858A true TW200507858A (en) 2005-03-01

Family

ID=32908675

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093104085A TW200507858A (en) 2003-02-20 2004-02-19 Formulations of glucocorticoids to treat pathologic ocular angiogenesis

Country Status (16)

Country Link
US (2) US20060074061A1 (https=)
EP (1) EP1594511A2 (https=)
JP (2) JP2006518383A (https=)
KR (1) KR20050102653A (https=)
CN (1) CN100431544C (https=)
AR (1) AR043252A1 (https=)
AU (1) AU2004212900A1 (https=)
BR (1) BRPI0407742A (https=)
CA (1) CA2516790A1 (https=)
MX (1) MXPA05008396A (https=)
PL (1) PL378209A1 (https=)
RU (1) RU2005129278A (https=)
TW (1) TW200507858A (https=)
UY (1) UY28203A1 (https=)
WO (1) WO2004073608A2 (https=)
ZA (1) ZA200505990B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
US9693967B2 (en) 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
BRPI0615563A2 (pt) * 2005-09-07 2011-05-24 Southwest Res Inst formulações farmacêuticas em micropartìcula biodegradável exibindo taxas de liberação aperfeiçoadas
KR20080087814A (ko) * 2005-12-22 2008-10-01 알콘 리서치, 리미티드 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
KR20100051811A (ko) * 2007-07-20 2010-05-18 알콘, 인코퍼레이티드 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제
ES2566934T3 (es) * 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
WO2015191795A1 (en) * 2014-06-12 2015-12-17 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
CA2383499C (en) * 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
JP2003511204A (ja) * 1999-10-21 2003-03-25 アルコン，インコーポレイティド テノン下薬剤送出
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ES2244361T1 (es) * 2002-08-05 2005-12-16 Alcon, Inc. Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad.

Also Published As

Publication number Publication date
UY28203A1 (es) 2004-08-31
JP2007056041A (ja) 2007-03-08
US20060074061A1 (en) 2006-04-06
CN1750829A (zh) 2006-03-22
AR043252A1 (es) 2005-07-20
EP1594511A2 (en) 2005-11-16
PL378209A1 (pl) 2006-03-20
AU2004212900A1 (en) 2004-09-02
ZA200505990B (en) 2006-12-27
CA2516790A1 (en) 2004-09-02
WO2004073608A2 (en) 2004-09-02
RU2005129278A (ru) 2006-01-27
MXPA05008396A (es) 2006-03-30
WO2004073608A3 (en) 2005-03-24
US20040167109A1 (en) 2004-08-26
BRPI0407742A (pt) 2006-02-14
CN100431544C (zh) 2008-11-12
JP2006518383A (ja) 2006-08-10
KR20050102653A (ko) 2005-10-26

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
NO20054988D0 (no) Preparater og metoder for behandling av cancer
UA91521C2 (ru) Композиции, содержащие липазу, протеазу и амилазу, предназначенные для лечения недостаточности поджелудочной железы
WO2004037184A3 (en) Methods for the treatment of skin disorders
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
MXPA05013075A (es) Inhibidores de p-38 basados en heterociclo de 5 miembros.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
GB9807639D0 (en) Anti-inflammatory agents
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
TW200507858A (en) Formulations of glucocorticoids to treat pathologic ocular angiogenesis
WO2004073607A3 (en) Use of steroids to treat ocular disorders
AU9157901A (en) Methods of treating inflammatory and immune reactions and compositions therefor
AU2001282990A1 (en) Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
GB2400556B (en) Therapeutic composition for autoimmune conditions
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
AU2003263988A1 (en) Methods and compositions to treat conditions associated with neovascularization
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
MX2010004315A (es) Compuestos para inhibir la actividad de quinesina ksp.
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
MXPA04007007A (es) Uso de inhibidores del intercambiador cloruro/bicarbonato dependiente del sodio para el tratamiento de enfermedades tromboticas e inflamatorias.
DE50112512D1 (de) Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel
WO2000062769A3 (en) Use of ap-1 activators to treat glaucoma and ocular hypertension